Top Stories Archives - Page 47 of 1424

2 minute read

Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations

June 6, 1:19 PM

Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis.

NVS

2 minute read

Chinese EV Maker NIO Partners With Melexis For Advanced Sensor Technology

By Shivani Kumaresan

June 6, 1:11 PM

China's EV maker NIO has selected Melexis' cutting-edge current sensor chips for its traction inverter systems. These advanced sensors, vital for electric motor control, will be featured in all NIO battery electric vehicles. This collaboration enhances NIO's vehicle efficiency and reliability.

NIO

2 minute read

Was The Ethereum ETF Approval Accelerated Because The ‘Political Wind Shifted So Fast?’

By Khyathi Dalal

June 6, 1:03 PM

Scott Melker in his recent "The Wolf of All Streets" podcast discussed the upcoming Spot Ethereum (CRYPTO: ETH) ETF and its potential ramifications

ETH

1 minute read

AbbVie’s Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients

By Vandana Singh

June 6, 1:02 PM

AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate.

ABBV

2 minute read

Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released

By Vandana Singh

June 6, 12:43 PM

4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease.

FDMT

2 minute read

Broadcom Rises As Top AI Chip Supplier After Nvidia, Thanks To Google And Meta Partnerships: Analyst

By Anusuya Lahiri

June 6, 12:32 PM

Broadcom, the global No. 2 AI semiconductor supplier behind Nvidia, has an Overweight rating with a price target of $1,700.

AVGO

2 minute read

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?

By Vandana Singh

June 6, 12:16 PM

Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was well-tolerated.

BMY

2 minute read

JPMorgan: US Crypto Regulations Signal Opposition To CBDCs And Non-Compliant Stablecoins

By Murtuza Merchant

June 6, 12:15 PM

A recent report by JPMorgan (NYSE:JPM) casts doubt on the immediate future of cryptocurrency regulation in the United States.

$USDT

2 minute read

Is Robinhood’s Crypto Exchange Deal Really ‘Massive’ And The ‘First Domino To Fall?’

By Murtuza Merchant

June 6, 12:11 PM

Robinhood's acquisition of Bitstamp has sparked varied reactions from experts, with CEO Tenev highlighting the potential of crypto to revolutionize finance.

HOOD

2 minute read

Eli Lilly’s Alzheimer’s Drug, Donanemab Faces FDA’s Adcomm Vote Next Week On Data, Risk Profile

By Vandana Singh

June 6, 12:07 PM

The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10. This review assesses the drug's benefit-risk profile based on significant efficacy results in cognition and daily function.

LLY